Korean Circ J.  2019 Aug;49(8):721-723. 10.4070/kcj.2019.0150.

Diffuse Long Coronary Artery Disease is Still an Obstacle for Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era?

Affiliations
  • 1Division of Cardiology, Department of Internal Medicine, Gachon University College of Medicine, Gachon University Gil Medical Center, Incheon, Korea. shhan@gilhospital.com

Abstract

No abstract available.


MeSH Terms

Coronary Artery Disease*
Coronary Vessels*
Drug-Eluting Stents*
Percutaneous Coronary Intervention*

Figure

  • Figure 1 One-year incidence of MACE or TLF after implantation of R-ZES for diffuse long coronary artery disease. MACE = major adverse clinical event; R-ZES = Resolute™ zotarolimus-eluting stent; TLF = target lesion failure.


Reference

1. Gwon HC, Jeon DW, Kang HJ, et al. The practice pattern of percutaneous coronary intervention in Korea: based on year 2014 cohort of Korean percutaneous coronary intervention (K-PCI) registry. Korean Circ J. 2017; 47:320–327.
Article
2. Bourassa MG, Lespérance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1991; 18:368–376.
Article
3. Park KH, Ahn Y, Koh YY, et al. Effectiveness and safety of zotarolimus-eluting stent (Resolute™ integrity) in patients with diffuse long coronary artery disease. Korean Circ J. 2019; 49:709–720.
Article
4. Taniwaki M, Stefanini GG, Silber S, et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63:1617–1625.
5. Patra S, Chakraborty RN, Pande A, et al. Zotarolimus-eluting resolute integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis. Cardiovasc Revasc Med. 2017; 18:160–164.
6. Chang SH, Chen CC, Hsieh MJ, Wang CY, Lee CH, Hsieh IC. Lesion length impacts long term outcomes of drug-eluting stents and bare metal stents differently. PLoS One. 2013; 8:e53207.
Article
7. Lee M, Hiremath S, Zambahari R, Leon M, Mauri L, Yeung A. RESOLUTE US and RESOLUTE Asia Investigators. One-year outcomes of percutaneous coronary intervention with the 38-mm Resolute zotarolimus-eluting stent. Am J Cardiol. 2013; 112:1335–1341.
Article
8. Bahuleyan CG, Krishna Kumar VV, Babu S. Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions. Indian Heart J. 2015; 67:233–238.
Article
9. Ahn JM, Park DW, Kim YH, et al. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Circ Cardiovasc Interv. 2012; 5:633–640.
10. Hong SJ, Kim BK, Shin DH, et al. Effect of Intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA. 2015; 314:2155–2163.
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr